High Intensity Contact Ultrasound Interstitial Medical Device

Clinical Indications targeted by the SonoProbe

Given the neurosurgical specialty of Pr. Carpentier, the SonoProbe was designed to be used for the treatment of a range of indications in the brain: tumors, epileptic lesions, radiosurgery resistant metastases, meningiomas … with a net annual incidence in Europe and in the United States of more than 400,000 patients.

Due to its design, the SonoProbe can also be adapted for the treatment of diseases in other organs. It potentially can also be used for treatments in moving organs or in organs hidden by bony structures (liver, lung …)

Below, the two main stages of treatment of a brain tumor by the SonoProbe are described.


The SonoProbe treatment

The first step is diagnostic. It begins with local anesthesia and stereotactic insertion of the probe within the tumor. A biopsy is performed to determine the precise histological status of the tumor. In the same step, still under local anesthesia, the treatment can take place.





The second step is therapeutic. It happens within the MRI scanner. After verification by MRI of the exact positioning of the probe relative to the tumor, treatment planning is performed. The treatment can then begin, with continuous monitoring using MR images acquired in real-time. The treatment itself lasts between 5 and 15 minutes. At the end of the procedure, the patient is discharged from the MRI, the probe is removed, and the patient is able to leave the hospital (the same day).



  • unnamed-2

  • News CarThera

    May 2018 – CarThera will participate to BIO 2018 in Boston

    CarThera will participate to the BIO International Convention in Boston on June 4-7 to meet with global biotech and pharma leaders and showcase its SonoCloud device.

    Should you want to meet us at BIO and hear more about SonoCloud – our ultrasound device, aimed at improving treatment efficiency by temporarily opening the Blood Brain Barrier – contact us at and come to Booth 527 at the France Pavilion.

    CarThera presented data from phase 1/2a study at 2017 ASCO annual meeting

    June 2017 – Dr. Ahmed Idbaih, AP-HP principal investigator of the Phase 1/2a clinical trial (NCT02253212) on ultrasound induced Blood-Brain Barrier opening revealed preliminary safety and efficacy data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

    The clinical data from the trial involving 21 patients with recurrent glioblastoma, who have all been treated with SonoCloud® low-intensity pulsed ultrasound in a total of 65 sessions, have been shared with more than 30,000 oncology professionals from around the world.

    CarThera secures €5.7 million in funding for its DOME project

    October 12, 2016 – CarThera has received a grant of €5.7 million ($6.4m) for its DOME project. The funding was awarded under the call for proposals ‘Structuring R&D Projects for Competitiveness’ from France’s ‘Investments for the Future Program’, led by the General Investment Commission and run by Bpifrance.

    The grant will finance our SonoCloud Phase 2b/3 study in glioblastoma that will involve around 200 patients at centers in Europe and the United States. It will also fund a number of exploratory studies, including one on Alzheimer’s disease, building on the findings from the Phase 1/2a study that paved the way for a broader array of clinical indications.